1 r the intestinal absorption of vitamin D(2) (ergocalciferol).

2  be revised to include even higher dosing of ergocalciferol.

3  In healthy persons with low 25(OH)D(total), ergocalciferol administration for 12 wk normalizes 25(OH

4 rform a detailed assessment of the effect of ergocalciferol administration on glucose and insulin met

5 g/ml at baseline to 39.2+/-14.9 ng/ml in the ergocalciferol arm and did not change (16.9+/-6.4 ng/ml

6 conclusion, 6 months of supplementation with ergocalciferol increased serum 25(OH)D levels in patient

7 o assess the effects of supplementation with ergocalciferol on epoetin utilization and other secondar

8  change in epoetin dose over 6 months in the ergocalciferol or placebo arms (geometric mean rate 0.98

9  276 patients were randomized to 6 months of ergocalciferol or placebo.

10 riol or vitamin D/aa[analogs & derivates] or ergocalciferol or vitamin D/bl[blood]; and with accident

11 the recommended course of 400,000 IU of oral ergocalciferol over 2 months, and only five (8%) respond

12 e recommended second course of 800,000 IU of ergocalciferol over 2 months, none demonstrated correcti

13 elow 30 ng/ml, and the currently recommended ergocalciferol repletion regimen often does not fully co

14  determined that dried mushrooms can produce ergocalciferol under UVB irradiation.

15                                 The onset of ergocalciferol (vitamin D(2)) formation was immediate in

16                We explored concentrations of ergocalciferol (vitamin D2) and cholecalciferol (vitamin

17                           Absorption of oral ergocalciferol (vitamin D2) and the consequent response

18  (by immunoassay) and administered 50,000 IU ergocalciferol/wk or placebo for 12 wk.